	The European Medicines Agency (EMA) opened up for consultation product-specific guidance documents on bioequivalence studies for the active substances asenapine, prasugrel, sitagliptin, and zonisamide.  The release of the guidance documents follows finalization of bioequivalence guidance on 16 active substances in 2014 and 2015.

	The guidance documents, which can be found on EMA’s 

, are available for comment until Nov. 1, 2015.

API Synthesis and Manufacturing, Large Molecule

Development

Industry News

News

Quality/GMPs

Regulatory Authority Actions

Regulatory/GMP Compliance

The agency has released guidance on bioequivalence studies for asenapine, prasugrel, sitagliptin, and zonisamide.